Navigation Links
Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
Date:9/4/2007

MIAMI LAKES, Fla., Sept. 4 /PRNewswire/ -- In an extensive analysis of clinical trials known as a meta-analysis, the CYPHER(R) Sirolimus-eluting Coronary Stent was associated with significantly lower risks of blood clots and the need for reintervention compared to the Taxus Stent out to 30 months after an angioplasty procedure. This meta-analysis of 16 randomized clinical trials and 8,695 patients, the largest analysis of its kind to date, is now posted on the Journal of the American College of Cardiology website and is expected in print later in the year.

"Over the past year, concerns have been raised regarding the long-term safety of all drug-eluting stents," said Professor Albert Schomig, M.D., from Deutsches Herzzentrum, Technische Universitat in Munich, Germany, one of the authors of the study. "In this meta-analysis of randomized controlled trials, the CYPHER(R) Stent was associated with a significant reduction in the risks of stent thrombosis and reintervention compared to the Taxus Stent. This reinforces the notion that there are marked differences between the CYPHER(R) Stent and the Taxus Stent and that the safety of these drug-eluting stents must be assessed separately."

Professor Schomig added, "We find these data compelling because they are consistent with other documented meta-analyses and reflect data from all of the randomized clinical trials directly comparing these drug-eluting stents. Meta-analyses like this are an important and well-accepted statistical method among clinicians worldwide for documenting similarities and differences between two treatment modalities. We understand and appreciate that such studies are open to various interpretations by researchers and clinicians."

The primary safety endpoint of the meta-analysis was protocol-defined stent thrombosis while the secondary safety endpoints were death and heart attack (myocardial infarction or MI). The primary efficacy endpoint was the need for reintervention (targ
'/>"/>

SOURCE Cordis Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
2. Largest National U.S. Healthcare Facility MRSA Study Reveals Infection Rates Eight Times Greater Than Previous Estimates
3. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
4. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
5. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2015)... 2015  Recognizing the unique position Massachusetts ... the most respected organizations in the New England medtech community, ... Industry Council (MassMEDIC), have partnered to celebrate the region,s ... Annual Massachusetts Medtech Week. This celebration will take place May ... Center in Boston . For more information ...
(Date:4/27/2015)... Mass. , April 27, 2015 ... a collaboration with Brainlab AG, a leading software-driven ... planning and surgical navigation. The collaboration provides patients ... Stimulation (DBS) therapy. DBS is intended to treat ... help reduce symptoms for movement disorders such as ...
(Date:4/27/2015)... , April 27, 2015  CryoLife, Inc. (NYSE: ... processing company focused on cardiac and vascular surgery, announced ... the United States Food and Drug Administration ("FDA") verifying ... in place following the warning letter it received from ... letter follows a re-inspection in March 2015 by the ...
Breaking Medicine Technology:First Annual Massachusetts Medtech Week Celebrated this May 2First Annual Massachusetts Medtech Week Celebrated this May 3Boston Scientific Announces Strategic Collaboration With Brainlab AG 2Boston Scientific Announces Strategic Collaboration With Brainlab AG 3Boston Scientific Announces Strategic Collaboration With Brainlab AG 4CryoLife Announces Resolution of FDA Warning Letter 2
... for,rheumatoid arthritis (RA) have ushered in a new ... The findings are,reported in a New Drug Class ... of The Lancet. , RA is the most ... of the,population in the industrialised world. Its typical ...
... WIRE)--Jun 13, 2007 - EPIX,Pharmaceuticals, Inc. (NASDAQ: EPIX) ... of PRX-00023, a novel long-acting 5-HT1A agonist,was featured ... New,Clinical Drug Evaluation Unit (NCDEU) Meeting in Boca ... Institutes of,Health and the American Society of Clinical ...
Cached Medicine Technology:Three New Drugs Mark New Era in Rheumatoid Arthritis Treatment 2Three New Drugs Mark New Era in Rheumatoid Arthritis Treatment 3EPIX Pharmaceuticals Presents Findings from PRX-00023 Phase 3,Clinical Trial at 47th Annual NCDEU Meeting 2EPIX Pharmaceuticals Presents Findings from PRX-00023 Phase 3,Clinical Trial at 47th Annual NCDEU Meeting 3EPIX Pharmaceuticals Presents Findings from PRX-00023 Phase 3,Clinical Trial at 47th Annual NCDEU Meeting 4
(Date:4/27/2015)... Texas (PRWEB) April 27, 2015 Fitness ... the Nation, is starting a health and fitness revolution, ... the fight against obesity. For several years, Houston, the ... one of the fattest cities in America. With help ... and make it one of the fittest and healthiest ...
(Date:4/27/2015)... Los Angeles, CA (PRWEB) April 27, 2015 ... titled “How to Get Rid of Stretch Marks ,” ... stretch marks . Stretch marks are a ... women. Stretch marks are caused by a breakdown of the ... beneath the epidermis. (see: goo.gl/iRdmEe) , “Stretch mark removal ...
(Date:4/27/2015)... According to a recent report from NIDCR ... back pain, TMJ disorders are the second most ... In addition, the report revealed that TMJ disorders affect ... an estimated 4 billion dollars annually. , These estimates ... unrelated symptoms such as headaches, neck pain, tenderness of ...
(Date:4/27/2015)... Thanks to a $7.5 million grant ... half-dozen institutions, including American University, will operate in a ... and behavioral research aimed at ending the AIDS epidemic. ... with HIV or AIDS, according to the latest statistics. ... population over the age of 13 was living with ...
(Date:4/27/2015)... 27, 2015 Doctors on Liens ... a lien basis for over twenty years. So when attorneys ... best doctor in the Fresno area , Doctors on ... and his team of medical specialists. With a medical ... therapist, Dilanchian Chiropractic is now helping more personal ...
Breaking Medicine News(10 mins):Health News:Houston Celebrities Take a Stand and Rebel Against Obesity 2Health News:Stretch Marks: The Latest Treatment Options for Stretch Mark Removal 2Health News:Dentist in Graham NC Reveals that a Jaw Disorder May Be the Cause of Chronic Headaches and Back Pain 2Health News:D.C. Center for AIDS Research Established with New Grant from NIH 2Health News:D.C. Center for AIDS Research Established with New Grant from NIH 3Health News:Eminent Doctor Joins Forces with Doctors on Liens in Fresno 2
... a recognized leader in providing turnkey electronic billing ... announced today that it has signed an agreement ... Corporation, to provide electronic clearinghouse services for Aon ... will enable Aon eSolutions, clients and medical providers ...
... highlights new hospitalist HIDI(TM) process at the 2009 ... ExecutivesSEATTLE, March 23 Hospital executives find themselves ... percent of America,s hospitals now operating at a ... Hospital leaders seek to control costs while maintaining ...
... Adds Advanced Drug Safety and Risk Management Applications to Extend ... News Facts , , ... that it has agreed to acquire Relsys International, Inc. ("Relsys"), ... with advanced analytics for the health sciences industry. , ...
... Volumes Seen in Houston Physician-Owned Hospitals, According ... 23 HealthLeaders-InterStudy, a leading provider of ... Texas laws favoring physicians have traditionally enabled ... directly with health systems, these regulations may ...
... (Nasdaq: WBMD ), the leading provider of ... a long-term strategic relationship with Boots UK Limited, the ... Kingdom, to jointly develop a consumer health and wellness ... will leverage WebMD,s online consumer health assets and expertise ...
... 23 Dr. Kevin Polk, a clinical psychologist with ... offering a new web program and DVD for stress ... Training (ACT). It emphasizes decreasing struggling with stress and ... traditional stress management techniques such as deep breathing and ...
Cached Medicine News:Health News:WorkCompEDI Announces Agreement with Aon eSolutions for Electronic Billing Services 2Health News:Sound Inpatient Physicians Report on New Clinical Processes to Reduce Healthcare Costs and Enhance Care 2Health News:Oracle Buys Relsys 2Health News:Oracle Buys Relsys 3Health News:In Texas, Favorable Regulations for Physicians May Backfire in Light of Market Downturn 2Health News:WebMD Announces Strategic Relationship with Boots UK to Launch New Consumer Health Portal in UK 2Health News:WebMD Announces Strategic Relationship with Boots UK to Launch New Consumer Health Portal in UK 3Health News:Surfing Your Stress to Success Program Offers a New Way of Dealing with Stress 2
Set of six replacement burrs for E0824 Storz corneal burr set. Dull finish. Most popular size or model....
Replacement burr for E0819A or E0819B Algerbrush rust ring remover. Dull finish....
0.5 mm replacement burr for Algerbrush rust ring remover (E0815 A). Burr can also be used with Algerbrush rust ring remover (E0815 B). Dull finish....
5.5 mm disk shape burr. Diamond coated tip. Use with E0824 B handle....
Medicine Products: